autoimmune diseases

InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV).  The trial demonstrated a comparable clinical response of vilobelimab to the standard of care, significantly reducing the...

Selecta Biosciences Inc (NASDAQ: SELB) has announced a strategic licensing agreement to advance a next-generation IgG protease.  The partnership leverages Genovis' immunoglobulin G (IgG) protease, IdeXork (Xork), and Selecta's ImmTOR platform to enable the dosing of...

Brickell Biotech Inc (NASDAQ: BBI) has entered into a definitive agreement with Voronoi Inc for exclusive, worldwide rights to therapeutics generated from a proprietary DYRK1A inhibitor platform. The DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific sequence originally isolated from synovial fluid of rheumatoid arthritis patients....

Cabaletta Bio Inc (NASDAQ: CABA) has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris (mPV). Related: Cabaletta Announced Favorable Safety Profile From First Cohort Of Phase 1 Study....

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held Thunderbolt Pharma Inc.  AUR200 is a recombinant Fc fusion protein designed to...

Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN). The new data showed that patients without a diagnosis of LN but with elevated urine protein/...

Moderna Inc (NASDAQ: MRNA) has dosed the first patient in the Phase 1 study of mRNA-6231, its mRNA-encoded IL-2 modified to expand regulatory T cells.  mRNA-6231 is Moderna's first autoimmune candidate to enter the clinic. It is also Moderna's first subcutaneously...

Alpine Immune Sciences Inc (NASDAQ: ALPN) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL...

Pandion Therapeutics Inc (NASDAQ: PAND) shares closed over 133% higher today. What Happened: Pandion — a developer of novel therapeutics targeting autoimmune diseases — will be acquired by a subsidiary of drug multinational Merck & Co, Inc (NYSE: MRK), according to a statement...

When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...

The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s prospects. But the generic drug developer scored one new advocate Thursday on the basis of its pipeline potential. The Rating Stifel Nicolaus analyst Alex Schwartz upgraded Momenta from Hold to Buy and...